NEW YORK (GenomeWeb) – Invitae and Alnylam Pharmaceuticals have together launched a free genetic testing service called Alnylam Act to encourage early testing and diagnosis for hereditary ATTR amyloidosis.

Through this program, funded by Alnylam, Invitae will perform free testing using one of its comprehensive gene panels for cardiomyopathy, neuropathy, or amyloidosis. Patients eligible for free testing are those in the US who are suspected to have the disease or a family history of it.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.